BioCentury | Nov 20, 2020
Translation in Brief

Long-term gene therapy study in dogs with hemophilia A; plus a comparison of HBV vaccine adjuvants and mAb that alleviates chemotherapy side effects

Long-term study of AAV gene therapy in dogs finds genome integration, clonal expansionA team led by University of Pennsylvania scientists showed in Nature Biotechnology that adeno-associated viral (AAV8 or AAV9) gene therapy corrected factor VIII...
BioCentury | Nov 11, 2020
Emerging Company Profile

CatalYm: opening up tumors to immune cells

CatalYm is targeting a lesser known immunosuppressant function of GDF15 to resensitize cancer patients to checkpoint blockade and enhance the ability of CAR T therapies to infiltrate solid tumors. The Munich-based biotech has raised €50 million...
BioCentury | Jul 18, 2020
Translation in Brief

Fate licenses rejection-resistant T cell therapies; plus a marker for anti-PD-1 treatment responsiveness, a cell proliferation control switch and more

Baylor’s engineered T cells designed to avoid immune rejection Baylor College of Medicine has granted Fate Therapeutics Inc. (NASDAQ:FATE) an exclusive license to alloimmune defense receptors, which render allogeneic cell therapies resistant to host immune...
BioCentury | Jul 16, 2020
Emerging Company Profile

Fountain Therapeutics: an AI-based platform to reverse cellular aging

Fountain is using an unbiased data-driven approach to identify compounds that reverse the biological process of aging, and in contrast to the traditional disease hypothesis-driven approach, the company is agnostic to indication. “Eighty percent of...
BioCentury | Mar 11, 2020
Product Development

Novo’s year of obesity

Novo Nordisk is set to deliver six clinical readouts in obesity in 2020. If successful, they could deliver Novo an opportunity to dramatically expand a mostly untapped market that could become a major future growth...
BioCentury | Dec 19, 2019

Promoting calcium channel signaling in muscle to treat age-related atrophy

DISEASE CATEGORY: Musculoskeletal INDICATION: Muscular atrophy Increasing signaling through the embryonic isoform of the skeletal muscle-specific calcium channel CACNB1 or its downstream effector GDF5 could treat age-related muscular atrophy. Transcript levels of both proteins were...
BioCentury | Oct 9, 2019
Company News

CTFH latest to partner with Insilico in AI discovery deal

In the latest addition to a growing roster of industry collaborations, AI company Insilico has partnered with CTFH to discover and develop two programs for triple-negative breast cancer. Insilico Medicine Inc. is eligible to receive...
BioCentury | Apr 12, 2019
Clinical News

Acceleron discontinues ACE-2494 due to antidrug antibodies

Acceleron discontinued development of ACE-2494 due to the frequency of antidrug antibodies observed among healthy volunteers in a Phase I trial. Acceleron Pharma Inc. (NASDAQ:XLRN) was developing ACE-2494 as a potential treatment of neuromuscular disorders....
BioCentury | Mar 26, 2019
Financial News

NGM could get $975M valuation in NASDAQ IPO

After setting its NASDAQ IPO terms on Monday, NGM would be valued at $975 million if it prices the offering at the midpoint of its proposed range. The valuation includes a concurrent private placement of...
BioCentury | Mar 22, 2019
Company News

Merck extends discovery partnership with NGM, drops obesity candidate

Merck & Co. said it will extend by two years its research collaboration with NGM and provide an additional $20 million in R&D funding. The pair initially partnered for five years in 2015 to discover...
Items per page:
1 - 10 of 53